Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | 23-cyclic-nucleotide 2-phosphodiesterase | 0.0148 | 0.3764 | 0.0209 |
Treponema pallidum | 5'-nucleotidase (ushA) | 0.0148 | 0.3764 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.0293 | 1 | 1 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0293 | 1 | 0.5 |
Schistosoma mansoni | 23-cyclic-nucleotide 2-phosphodiesterase | 0.0148 | 0.3746 | 0.018 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0293 | 1 | 0.5 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0293 | 1 | 0.5 |
Echinococcus granulosus | p2X purinoceptor 4 | 0.0293 | 1 | 0.5 |
Echinococcus multilocularis | p2X purinoceptor 4 | 0.0293 | 1 | 0.5 |
Schistosoma mansoni | P2X receptor subunit | 0.0293 | 1 | 1 |
Toxoplasma gondii | 5'-nucleotidase, C-terminal domain-containing protein | 0.0148 | 0.3764 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.